MX2021009868A - Nuevo derivado de pirido[3,4-d]pirimidin-8-ona que tiene actividad inhibidora de proteína cinasa y composición farmaceutica para prevenir, aliviar o tratar el cáncer, que comprende el mismo. - Google Patents
Nuevo derivado de pirido[3,4-d]pirimidin-8-ona que tiene actividad inhibidora de proteína cinasa y composición farmaceutica para prevenir, aliviar o tratar el cáncer, que comprende el mismo.Info
- Publication number
- MX2021009868A MX2021009868A MX2021009868A MX2021009868A MX2021009868A MX 2021009868 A MX2021009868 A MX 2021009868A MX 2021009868 A MX2021009868 A MX 2021009868A MX 2021009868 A MX2021009868 A MX 2021009868A MX 2021009868 A MX2021009868 A MX 2021009868A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- pyrimidin
- alleviating
- preventing
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente exposición se refiere a un compuesto derivado de pirido[3,4-d]pirimidin-8-ona que presenta excelentes efectos antiproliferativos contra las células cancerosas, una sal farmacéuticamente aceptable del mismo, un hidrato del mismo o un estereoisómero del mismo, un método de producción del mismo, una composición farmacéutica para prevenir, aliviar o tratar la metástasis del cáncer y la enfermedad. proliferativa que lo contiene como ingrediente activo, y una composición anticancerígena contra las células cancerosas. El compuesto exhibe una excelente actividad inhibidora de las células cancerosas y efectos antiproliferativos y, por lo tanto, es eficaz para inhibir las células cancerosas, prevenir la metástasis del cáncer y las enfermedades proliferativas o tratar el cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190018704A KR20200100429A (ko) | 2019-02-18 | 2019-02-18 | 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
| PCT/KR2020/002213 WO2020171499A1 (ko) | 2019-02-18 | 2020-02-17 | 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009868A true MX2021009868A (es) | 2022-01-04 |
Family
ID=72143523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009868A MX2021009868A (es) | 2019-02-18 | 2020-02-17 | Nuevo derivado de pirido[3,4-d]pirimidin-8-ona que tiene actividad inhibidora de proteína cinasa y composición farmaceutica para prevenir, aliviar o tratar el cáncer, que comprende el mismo. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220135559A1 (es) |
| EP (1) | EP3929195A4 (es) |
| JP (1) | JP7262599B2 (es) |
| KR (1) | KR20200100429A (es) |
| AU (1) | AU2020225048B2 (es) |
| BR (1) | BR112021016132A2 (es) |
| CA (1) | CA3130568A1 (es) |
| MX (1) | MX2021009868A (es) |
| WO (1) | WO2020171499A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| JP2022546043A (ja) | 2019-08-29 | 2022-11-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| CN114761012A (zh) | 2019-09-24 | 2022-07-15 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| BR112022012106A2 (pt) | 2019-12-20 | 2022-09-20 | Mirati Therapeutics Inc | Inibidores de sos1 |
| KR102396930B1 (ko) * | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| CA3198943A1 (en) | 2020-11-18 | 2022-05-27 | Daniel L. Flynn | Gcn2 and perk kinase inhibitors and methods of use thereof |
| WO2023239165A1 (ko) * | 2022-06-08 | 2023-12-14 | 한국화학연구원 | 페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005011587A2 (en) * | 2003-07-30 | 2005-02-10 | New Century Pharmaceuticls | Chalaropsis lysozyme protein and its method of use in anti-bacterial applications |
| CA2636981A1 (en) * | 2006-01-31 | 2007-08-09 | F. Hoffmann-La Roche Ag | 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| ITBO20130393A1 (it) | 2013-07-23 | 2015-01-24 | Ima Ind Srl | Dispositivo di saldatura ad ultrasuoni |
| JP6919922B2 (ja) * | 2016-12-19 | 2021-08-18 | アビスコ セラピューティクス カンパニー リミテッド | Ｆｇｆｒ４阻害剤、その製造方法と薬学的な応用 |
| TW201827422A (zh) * | 2017-01-13 | 2018-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | １，２，４－三嗪－３－胺類衍生物、其製備方法及其在醫藥上的應用 |
-
2019
- 2019-02-18 KR KR1020190018704A patent/KR20200100429A/ko not_active Application Discontinuation
-
2020
- 2020-02-17 EP EP20759694.1A patent/EP3929195A4/en active Pending
- 2020-02-17 WO PCT/KR2020/002213 patent/WO2020171499A1/ko unknown
- 2020-02-17 CA CA3130568A patent/CA3130568A1/en active Pending
- 2020-02-17 BR BR112021016132-5A patent/BR112021016132A2/pt unknown
- 2020-02-17 US US17/431,591 patent/US20220135559A1/en active Pending
- 2020-02-17 JP JP2021548608A patent/JP7262599B2/ja active Active
- 2020-02-17 MX MX2021009868A patent/MX2021009868A/es unknown
- 2020-02-17 AU AU2020225048A patent/AU2020225048B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3929195A1 (en) | 2021-12-29 |
| AU2020225048B2 (en) | 2023-02-23 |
| CN113646307A (zh) | 2021-11-12 |
| US20220135559A1 (en) | 2022-05-05 |
| WO2020171499A1 (ko) | 2020-08-27 |
| EP3929195A4 (en) | 2022-11-30 |
| CA3130568A1 (en) | 2020-08-27 |
| JP7262599B2 (ja) | 2023-04-21 |
| BR112021016132A2 (pt) | 2021-10-13 |
| KR20200100429A (ko) | 2020-08-26 |
| AU2020225048A1 (en) | 2021-09-16 |
| JP2022521901A (ja) | 2022-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009868A (es) | Nuevo derivado de pirido[3,4-d]pirimidin-8-ona que tiene actividad inhibidora de proteína cinasa y composición farmaceutica para prevenir, aliviar o tratar el cáncer, que comprende el mismo. | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| MX2022012780A (es) | Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados. | |
| MX2023008716A (es) | Compuesto de camptotecina, metodo de preparacion del mismo y aplicacion del mismo. | |
| MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
| NZ753459A (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| GEP20227434B (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| MX2008012422A (es) | Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa. | |
| MX2020003381A (es) | Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. | |
| MX2021012549A (es) | Derivados de tetrahidro-1h-ciclopenta[cd]indeno como inhibidores del factor inducible por hipoxia-2(alfa). | |
| EP4104837A3 (en) | Heterocyclic compounds as ret kinase inhibitors | |
| MX2015008396A (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
| CA2902116C (en) | Pyrrolopyridine derivatives and their use as inhibitors of ssao activity | |
| WO2021074620A9 (en) | [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors | |
| MX2021008667A (es) | Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo. | |
| JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). | |
| EP3819298A4 (en) | COMPOSITION WITH TRKA INHIBITIVE EFFECT AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR RELIEF OF PAIN THEREOF AS AN ACTIVE SUBSTANCE | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| EP4234021A3 (en) | Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy | |
| MX2018011592A (es) | Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo. | |
| MX2023003576A (es) | Compuesto como inhibidor de la akt cinasa. |